How does the CSL (ASX:CSL) dividend compare to its sector?

We look at how the CSL dividend measures up against its rivals.
The post How does the CSL (ASX:CSL) dividend compare to its sector? appeared first on The Motley Fool Australia. –

The CSL Limited (ASX: CSL) dividend ticked up a notch last earnings season due to the company outperforming its guidance. In particular, the global biotech’s CSL Behring and Seqirus business delivered robust growth in FY21.

The surging profits led the company to give back to its shareholders, reflecting its consistent dividends policy.

But let’s see how the CSL dividend stacks up against its rivals.

How does the CSL dividend stack up?

CSL is set to pay a fully franked final dividend of $1.59 per share to eligible investors on 30 September.

When combined with its interim dividend of $1.35 apiece, this brings the total FY21 dividend to $2.94, equalling FY20. It’s worth noting the board declared the first-half FY20 dividend payment (147 cents) just before the COVID-19 pandemic set in.

Based on the closing CSL share price of $312.01 last week, this gives a dividend yield of 0.94%.

What about its competitors?

The company’s main direct competitors are Spanish company Grifols (NAS: GRFS) and Japanese-owned Takeda Pharmaceutical Company (NYSE: TAK). However, as they are both not listed on the ASX, we take a look at Sonic Healthcare Ltd (ASX: SHL) and Ramsay Health Care Ltd (ASX: RHC).

By comparison, Sonic Healthcare rewarded its shareholders with a partially-franked final dividend of 55 cents per share on 22 September.

The full-year dividend, comprising of an interim dividend of 36 cents apiece, equates to 91 cents per share. This represents a 7.1% lift on the prior full-year dividend (FY20).

The Sonic Healthcare share price finished last week at $40.59 which gives it a dividend yield of 2.24%.

Its other competitor in the sector, Ramsay Health Care, is on track to distribute a final dividend of $1.03 per share to shareholders on 30 September. The company’s interim dividend for the FY21 period came to 48.5 cents a pop, translating to a full-year dividend of $1.515.

Calculating using the last price of $69.26 for Ramsay Health Care shares, this is a dividend yield of 2.19%. 

Comparing the CSL dividend yield against its peers may be one point to consider when investing. However, it is important to also look at the total shareholder return for the past 12 months.

As such, CSL shares have gained 5% for the period, while Sonic Healthcare and Ramsay Health Care shares have moved up 20% and 1 respectively.

Are CSL shares a buy?

A number of brokers weighed in after the company released its full-year results in mid-August.

Analysts at Jefferies slapped a “hold” rating on the CSL share price, cutting its outlook by 1.7% to $327.85. On the other hand, Morgans and Credit Suisse raised their price targets by 7.7% to $324.40 and 1.6% to $315.00 respectively.

However, the most recent broker note came from Citi which also raised its view on CSL shares by 4.8% to $325.00. Based on the current share price, this implies an upside of around 4.1% on Citi’s assessment.

CSL commands a market capitalisation of roughly $142.17 billion, making it the second-largest company on the ASX.

The post How does the CSL (ASX:CSL) dividend compare to its sector? appeared first on The Motley Fool Australia.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Is the CSL (ASX:CSL) share price in the buy zone?
How has the CSL (ASX:CSL) share price performed since FY21 results?
3 experts pick 3 ASX shares to rocket in next 12 months

Why is the ASX All Ordinaries (ASX:XAO) struggling lately?

The CSL (ASX:CSL) share price has had a good 6 months. Is it a buy?

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has recommended Ramsay Health Care Limited and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!